Man Group’s C4 Therapeutics CCCC Stock Holding History

Man Group’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Buy	408,648 +152,180	+59%	+$521K	﹤0.01%	1591
2026 Q1	$675K	Buy	256,468 +100,370	+64%	+$236K	﹤0.01%	1979
2025 Q4	$298K	Buy	156,098 +65,820	+73%	+$156K	﹤0.01%	2016
2025 Q3	$200K	Buy	90,278 +11,791	+15%	+$28.3K	﹤0.01%	2109
2025 Q2	$112K	Sell	78,487 -7,136	-8%	-$10.4K	﹤0.01%	2117
2025 Q1	$137K	Buy	+85,623	New	+$255K	﹤0.01%	2089
2024 Q2	–	Sell	-139,900	Closed	-$1.14M	–	2046
2024 Q1	$1.14M	Sell	139,900 -19,865	-12%	-$154K	﹤0.01%	1495
2023 Q4	$903K	Buy	+159,765	New	+$364K	﹤0.01%	1484
2023 Q3	–	Sell	-69,332	Closed	-$211K	–	1673
2023 Q2	$191K	Buy	+69,332	New	+$223K	﹤0.01%	1827
2023 Q1	–	Hold	0	–	–	–	1925
2021 Q4	–	Sell	-6,423	Closed	-$287K	–	1964
2021 Q3	$287K	Buy	6,423 +1,000	+18%	+$42.8K	﹤0.01%	1661
2021 Q2	$205K	Buy	+5,423	New	+$194K	﹤0.01%	1795

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Man Group's CCCC Position: Q2 2026 in Review

Man Group increased its C4 Therapeutics (CCCC) stake by 59% in Q2 2026, buying an estimated $521K and bringing the position to 408,648 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1591.

Man Group first reported a position in CCCC in Q2 2021 and has held it in 11 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Man Group held 408,648 shares of C4 Therapeutics worth $1.91M as of Q2 2026.
Man Group bought 152,180 C4 Therapeutics shares in Q2 2026, an estimated $521K.
C4 Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1591 holding.
Man Group first reported a position in C4 Therapeutics in Q2 2021 and has held it in 11 quarters since.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.